CHKM, ALXN, HOLI, FSIN, EXAR, MOS are Stocks to Watch on Dec-29 AfternoonBeacon Equity ResearchTheir market cap is 13.11B . Alexion Pharmaceuticals, Inc is engaged in the discovery, development and delivery of biologic therapeutic products and life-thr…
Leerink Swann Analysts Reiterate an "Outperform" Rating on Alexion …LocalizedUSA… development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the…
Alexion Pays $610M to Buy Enobia for Hypophosphatasia ERT CandidateGenetic Engineering News… Soliris and has leveraged its complement inhibition and antibody platforms to generate a clinical development-stage pipeline spanning the fields of hematolog…
Nasdaq 100 Updates Today: ALXN, ISRG, BIIB, ROST, DLTR, FAST, SBUX, ORLYEmerald Scope… development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the therap…
Top Losers in After-hours Today, Dec-28Beacon Equity Research… Inc is engaged in the discovery, development and delivery of biologic therapeutic products and life-threatening disease states, including hematologic and neurologic diseases, transplant r…
Face Transplants Offer High Yield With One ProcedureMedPage TodayIn this series, all three patients had some post-operative infections but recovered, and two of the patients had one episode each of acute rejection, successfully treated with pulsed dose…
Alexion Pharmaceuticals (ALXN) Shares Downgraded to a "Neutral" Rating by …LocalizedUSA… development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those…
RWANDA: Medics welcome Govt's approval of organ transplantsEast Africa News PostSome of the key areas for medical management are the problems of transplant rejection, during which the body has an immune response to the transplanted organ, possibly …
Bristol-Myers Squibb's Multi-Faceted UpsideSeeking AlphaIts products under Phase III clinical trials include Eliquis, to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Nulojix to prevent solid organ …
Bristol-Myers Squibb Looks to Continue to Trade Above its Annual-High Share …Financial News Network OnlineThe Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ …